Acute Intermittent Porphyria Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Acute Intermittent Porphyria Market is segmented By Treatment (RNA Interference-based Therapy, Givosiran, Symptomatic Treatment), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.
Acute Intermittent Porphyria Market Size
Taille du Marché en USD Bn
TCAC6.1%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 6.1% |
| Concentration du Marché | High |
| Principaux Acteurs | Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, Dicerna Pharmaceuticals, Moderna and Among Others. |
please let us know !
Acute Intermittent Porphyria Market Analysis
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The market has been expanding in recent years due to the rising prevalence of acute intermittent porphyria worldwide. Factors such as growing awareness about the condition and its treatment options are supporting the growth of this market.